Invivyd reported second quarter 2026 financial results with PEMGARDA net product revenue of $14.3 million, a 21% increase from the prior year period. The company posted a net loss of $44.4 million and ended the quarter with $160.1 million in cash and cash equivalents. R&D expenses rose to $29.4 million due to clinical trial costs for VYD2311, while SG&A increased to $29.5 million. Invivyd announced that the DECLARATION pivotal clinical trial enrollment is complete and top-line data is expected later in Q3 2026. Additionally, the LIBERTY study is fully dosed with results anticipated in late Q3 2026. The company also disclosed receipt of twelve months' advance notice regarding the potential termination of PEMGARDA's emergency use authorization effective June 29, 2027. Invivyd operates as a biopharmaceutical company developing monoclonal antibodies for viral infectious diseases.
